Pittenger & Anderson Inc. Has $3.91 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Pittenger & Anderson Inc. reduced its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 6.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,342 shares of the company's stock after selling 4,111 shares during the period. Pittenger & Anderson Inc.'s holdings in Novo Nordisk A/S were worth $3,912,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in NVO. Revolve Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after buying an additional 200 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Novo Nordisk A/S by 10.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 225,914 shares of the company's stock worth $19,433,000 after buying an additional 21,331 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after buying an additional 23,223 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $13,282,000. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Novo Nordisk A/S by 3,688.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 8,790 shares of the company's stock worth $756,000 after buying an additional 8,558 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NVO. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $68.93 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $307.77 billion, a P/E ratio of 20.39, a price-to-earnings-growth ratio of 1.34 and a beta of 0.64. The firm's fifty day simple moving average is $70.35 and its two-hundred day simple moving average is $75.00. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $143.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.